CAR-T cell therapy - Luminary Therapeutics
Latest Information Update: 30 Jun 2023
At a glance
- Originator Luminary Therapeutics
- Developer Luminary Therapeutics; University of North Carolina
- Class Antineoplastics; CAR-T cell therapies; Immunotherapies
- Mechanism of Action Chondroitin sulfate proteoglycan inhibitors; Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours